Categories Uncategorized

Astiva Health Inc. Expecting to Build Upon This Year’s Performance with Significant Membership Boost in 2025

  • The company anticipates a 70% increase in membership in the upcoming year, growing the current number of members from 13,000 in June 2024 to 20,000 in 2025.
  • The fourfold increase in membership reflects the growing demand for a change in approach to healthcare that combines innovative personalized strategies with a deep understanding of the served communities.
  • The company has established a strong network of over 12,940 providers, enabling it to offer comprehensive care to its rapidly growing member base, especially in Southern California.

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan, dedicated to reshaping personalized and comprehensive healthcare, anticipates strong growth in membership in 2025, building upon the record-setting performance already achieved this year in terms of network and membership expansion.

According to a company news release, membership is expected to grow by 70% or 7,000 members in the upcoming year, a major increase from the numbers reported this year (https://ibn.fm/VbZnF). Astiva Health started off with a membership jump in January 2024, when it reached 10,000 members (22% higher than the 3,100 members recorded in January 2023), and then again in June 2024 when 13,000 members were recorded.

This remarkable membership increase of more than four times reflects the growing demand for Astiva Health’s unique services and approach to healthcare. The company’s core mission is to efficiently deliver innovative health plans customized to meet its members’ specialized needs, including a culturally responsive approach to healthcare via multilingual solutions for customer service, marketing materials and educational resources.

“We are thrilled to continue building on the momentum we’ve achieved this year,” said Dr. Tri T. Nguyen, Co-founder and CEO of Astiva Health. “Our growth is a testament to the value our culturally aware, personalized healthcare model brings to our members. As we project adding another 7,000 members in 2025, we are committed to expanding our services and enhancing the quality of care we provide.”

Astiva Health’s dedication to serving the underserved population, particularly in Southern California, positioned the company to tap into a market segment with significant growth potential, and allowed it to consistently exceed growth expectations. In addition to the remarkable increase in membership, the company successfully established a strong network of over 12,940 providers, including 10,355 specialists and 2,585 primary care physicians, enabling it to offer comprehensive care to its rapidly growing member base.

Astiva Health also focuses on meeting the growing demand for quality Medicare Advantage plans, offering a type of plan with prescription drug coverage, so members have no need for a separate Part D plan. The company provides a range of options that prioritize member satisfaction and comprehensive care, with the goal of addressing the unique needs of seniors, providing access to extensive networks of healthcare providers and specialized services.

“Astiva Health’s commitment to excellence in healthcare has positioned us for this incredible growth trajectory,” said Chi Luong, CFO of Astiva Health. “As we look forward to 2025, we remain focused on delivering innovative healthcare solutions that cater to the unique needs of our diverse communities. We are excited about the opportunities ahead and remain dedicated to providing our members with the highest level of care.”

For more information, visit the company’s website at www.AstivaHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to Astiva are available in the company’s newsroom at https://ibn.fm/Astiva

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Study Identifies Genetic Marker Helpful in Guiding Brain Tumor Treatment

Researchers at the University of Kentucky have identified a key genetic biomarker that treatment teams…

3 days ago

New AI-Based Speech Tool Detects Possibility of Parkinson’s Disease

Computer scientists have designed an AI-based speech screening tool that could help people ascertain whether…

4 days ago

Why Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Is ‘One to Watch’

Izotropic is the only commercial entity with exclusive global rights to the Breast CT technology…

6 days ago

Study Discovers That Autoantibodies in Patients Could Boost Cancer Immunotherapy

For years, oncologists have been baffled by why checkpoint inhibitors work for some cancer patients…

6 days ago

Clene Inc. (NASDAQ: CLNN) Offers Investors a Compelling Entry into the Growing ALS Market with Key FDA Milestones for Lead Drug Candidate

Clene is progressing toward a potential FDA accelerated approval for its ALS (Amyotrophic Lateral Sclerosis)…

1 week ago

Survey Finds That US Healthcare Workers Worry About Personal Safety

According to a new survey, approximately 60% of workers in the U.S. healthcare sector are…

1 week ago